C. Grohe Et Al. , "Durvalumab +/- tremelimumab plus platinum-etoposide in first-line (1L) extensive-stage SCLC (ES-SCLC): Results from the phase 3 CASPIAN study," ONCOLOGY RESEARCH AND TREATMENT , vol.43, pp.149, 2020
Grohe, C. Et Al. 2020. Durvalumab +/- tremelimumab plus platinum-etoposide in first-line (1L) extensive-stage SCLC (ES-SCLC): Results from the phase 3 CASPIAN study. ONCOLOGY RESEARCH AND TREATMENT , vol.43 , 149.
Grohe, C., Paz-Ares, L. G., Dvorkin, M., Chen, Y., Hotta, K., Trukhin, D., ... Statsenko, G.(2020). Durvalumab +/- tremelimumab plus platinum-etoposide in first-line (1L) extensive-stage SCLC (ES-SCLC): Results from the phase 3 CASPIAN study. ONCOLOGY RESEARCH AND TREATMENT , vol.43, 149.
Grohe, C. Et Al. "Durvalumab +/- tremelimumab plus platinum-etoposide in first-line (1L) extensive-stage SCLC (ES-SCLC): Results from the phase 3 CASPIAN study," ONCOLOGY RESEARCH AND TREATMENT , vol.43, 149, 2020
Grohe, C. Et Al. "Durvalumab +/- tremelimumab plus platinum-etoposide in first-line (1L) extensive-stage SCLC (ES-SCLC): Results from the phase 3 CASPIAN study." ONCOLOGY RESEARCH AND TREATMENT , vol.43, pp.149, 2020
Grohe, C. Et Al. (2020) . "Durvalumab +/- tremelimumab plus platinum-etoposide in first-line (1L) extensive-stage SCLC (ES-SCLC): Results from the phase 3 CASPIAN study." ONCOLOGY RESEARCH AND TREATMENT , vol.43, p.149.
@article{article, author={C. Grohe Et Al. }, title={Durvalumab +/- tremelimumab plus platinum-etoposide in first-line (1L) extensive-stage SCLC (ES-SCLC): Results from the phase 3 CASPIAN study}, journal={ONCOLOGY RESEARCH AND TREATMENT}, year=2020, pages={149} }